Prescription medicine
Hydromorphone Brand names: Dilaudid; first approved as Dilaudid-Hp
Hydromorphone (Dilaudid) is a prescription medicine with an FDA approval on record since 1984. FDA's NDC Directory lists it from 13 generic labelers, and pharmacies paid $0.219 per hydromorphone 4 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- In shortage
- Boxed warning
- DEA Schedule II
Check it at the source: the hydromorphone FDA label on DailyMed (effective May 14, 2026, Rhodes Pharmaceuticals LLC); the NDA 19034 record on Drugs@FDA; every hydromorphone label on DailyMed.
Highlights of the record
FDA label of May 14, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE.
See full prescribing information for complete boxed warning. Ensure accuracy when prescribing, dispensing, and administering hydromorphone hydrochloride oral solution. Dosing errors due to confusion between mg and mL can result in accidental overdose and death. ( 2.1 , 5.1 ) Hydromorphone hydrochloride oral solution or hydromorphone hydrochloride tablets expose users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. ( 5.2 ) Serious, life-threatening, or fatal respiratory depression may occur, especially upon initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of hydromorphone hydrochloride oral solution or hydromorphone hydrochloride tablets are essential. ( 5.3 ) Accidental ingestion of hydromorphone hydrochloride oral solution or hydromorphone hydrochloride tablets, especially by children, can result in a fatal overdose of hydromorphone. […]
Used for
From the label: indications and usageHydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Forms and strengths
- 2 mg
- 4 mg
- 8 mg
- 12 mg
- 16 mg
- 32 mg
- 0.2 mg/ml
- 0.25 mg/.5ml
- 0.5 mg/.5ml
- 1 mg/ml
- 2 mg/ml
- 4 mg/ml
Tablet; injection (solution); extended-release tablet; solution; injection.
On the market
- Earliest approval on file
- January 11, 1984 Dilaudid-Hp, Fresenius Kabi Usa; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 23 first August 23, 1995; 14 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 17 of which 13 under generic applications, 4 under brand applications, repackagers included
- Last listed patent
- January 10, 2043 Hydromorphone Hydrochloride injection; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.219 per tablet Hydromorphone 4 mg tablet
- Shortage (FDA)
- 12 of 27 presentations limited or unavailable updated October 6, 2026
- Recalls by its makers (FDA)
- 30 since 2012 4 Class I among all firms' recalls; latest November 9, 2023; 85 more by firms not listed as its makers
- FAERS reports
- 91,453 through July 30, 2026
What is hydromorphone used for?
From the label: indications and usageHydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets contain hydromorphone, an opioid agonist, and are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. […]
Conditions named in the indications of hydromorphone's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Opioid Agonist.
Source: FDA drug label (Hydromorphone Hydrochloride), Rhodes Pharmaceuticals LLC, effective May 14, 2026 (SPL set 37565441-0d95-4743-a695-d7b3326f58a1), via openFDA; the full label on DailyMed
Is there a generic for hydromorphone (Dilaudid)?
The FDA approved the first generic hydromorphone on August 23, 1995. 23 generic applications are approved; 14 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists hydromorphone from 13 labelers under a generic (ANDA) application and from 4 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists no patent for Dilaudid tablets; a patent listed only for Hydromorphone Hydrochloride injection runs to January 10, 2043. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 1984 earliest approval on file
- 1995 first generic approved
- 2043 last listed patent
- 2017 to now in shortage
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for hydromorphone (Dilaudid)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.219 per Hydromorphone 4 mg tablet, up 11% from $0.198 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Hydromorphone 4 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Hydromorphone 1 mg/mL solution | Generic | $0.236 per mL | n/a | -22% |
| Hydromorphone 10 mg/mL vial | Generic | $2.57 per mL | n/a | n/a |
| Hydromorphone 2 mg tablet | Generic | $0.169 per tablet | $5.08 | +0.8% |
| Hydromorphone 2 mg/mL vial | Generic | $2.74 per mL | n/a | +0.6% |
| Hydromorphone 4 mg tablet | Generic | $0.219 per tablet | $6.57 | +11% |
| Hydromorphone 5 mg/5 mL solution | Generic | $0.236 per mL | n/a | -22% |
| Hydromorphone 50 mg/5 mL vial | Generic | $2.57 per mL | $12.83 per vial | n/a |
| Hydromorphone 500 mg/50 mL vial | Generic | $2.57 per mL | $128.31 per vial | n/a |
| Hydromorphone 500 mg/50 mL vial | Generic | $2.57 per mL | n/a | n/a |
| Hydromorphone 8 mg tablet | Generic | $0.561 per tablet | $16.83 | +3% |
| Hydromorphone HCl ER 12 mg tablet | Generic | $10.42 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $312.64 | -1% |
| Hydromorphone HCl ER 16 mg tablet | Generic | $12.38 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $371.41 | +29% |
| Hydromorphone HCl ER 8 mg tablet | Generic | $5.73 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $171.86 | -10% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is hydromorphone in shortage?
The FDA Drug Shortage Database lists 12 of 27 hydromorphone presentations as limited or unavailable (updated October 6, 2026); the first entry was posted on October 31, 2017. 14 more presentations are on the list as available.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11) | Fresenius Kabi USA, LLC | Current | September 15, 2026 |
| Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06) | Fresenius Kabi USA, LLC | Current | September 15, 2026 |
| Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11) | Fresenius Kabi USA, LLC | Current | October 6, 2026 |
| Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11) | Fresenius Kabi USA, LLC | Current | October 6, 2026 |
| Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01) | Hospira, Inc., a Pfizer Company | Current | September 22, 2026 |
| Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01) | Hospira, Inc., a Pfizer Company | Current | September 22, 2026 |
| Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37) | Hospira, Inc., a Pfizer Company | Current | September 22, 2026 |
| Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25) | Fresenius Kabi USA, LLC | Current | September 15, 2026 |
Every hydromorphone presentation in the FDA shortage database
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has hydromorphone been recalled?
The FDA's Enforcement Report lists 115 recalls naming hydromorphone since 2012: 4 Class I (the most serious), 110 Class II, 1 Class III; 2 still ongoing. 85 of them are by firms that FDA's NDC Directory does not list as a maker of hydromorphone and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| April 15, 2025 | Class III | OurPharma LLC not a listed maker | Superpotent Drug: Assay/potency result for hydromorphone HCl in the compounded stability lot was higher than specification.. |
| November 9, 2023 | Class II | SCA Pharmaceuticals, LLC | Lack of Assurance of Sterility |
| May 9, 2023 | Class II | SSM Health Care St. Louis DBA SSM St. Clare Health Center not a listed maker | CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity … |
| April 26, 2023 | Class II | Akorn, Inc. | CGMP Deviations: Firm went out of business and could no longer continue stability studies. |
| December 27, 2022 | Class II | Sentara Infusion Services not a listed maker | Lack of sterility assurance |
| June 30, 2022 | Class II | Nephron Sterile Compounding Center LLC not a listed maker | Lack of Assurance of Sterility |
| May 18, 2022 | Class II | Nephron Sterile Compounding Center LLC not a listed maker | Lack of Assurance of Sterility |
| December 17, 2020 | Class II | SCA Pharmaceuticals not a listed maker | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integral unit |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the hydromorphone label say about other medicines?
The hydromorphone label names 20 other medicines in its interaction, contraindication or warning sections. The labels of 4 other medicines name hydromorphone. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Buprenorphine | drug interactions | Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of hydromorphone hydrochloride oral solution or hydromorphone hydrochloride tablets and/or precipitate withdrawal symptoms. Intervention: Avoid concomitant use. Examples: Butorphanol, nalbuphine, pentazocine, and buprenorphine. |
| Butorphanol | drug interactions | Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of hydromorphone hydrochloride oral solution or hydromorphone hydrochloride tablets and/or precipitate withdrawal symptoms. Intervention: Avoid concomitant use. Examples: Butorphanol, nalbuphine, pentazocine, and buprenorphine. |
| Cyclobenzaprine | drug interactions | Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. … (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as … |
| Fentanyl | warnings and precautions | Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine/day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer. |
| Gabapentin | drug interactions | Benzodiazepines and other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. … anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), other opioids, alcohol. |
| Linezolid | drug interactions | Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. … inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). |
| Metaxalone | drug interactions | Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. … mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and … |
| Methylene blue | drug interactions | Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. … psychiatric disorders and also others, such as linezolid and intravenous methylene blue). |
| Mirtazapine | drug interactions | Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. … antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those … |
| Morphine | warnings and precautions | Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine/day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer. |
| Nalbuphine | drug interactions | Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of hydromorphone hydrochloride oral solution or hydromorphone hydrochloride tablets and/or precipitate withdrawal symptoms. Intervention: Avoid concomitant use. Examples: Butorphanol, nalbuphine, pentazocine, and buprenorphine. |
| Nalmefene | warnings and precautions | Management of respiratory depression may include close observation, supportive measures, and use of opioid overdose reversal agents (e.g., naloxone, nalmefene), depending on the patient's clinical status [see Overdosage (10) ]. |
| Naloxone | warnings and precautions | Management of respiratory depression may include close observation, supportive measures, and use of opioid overdose reversal agents (e.g., naloxone, nalmefene), depending on the patient's clinical status [see Overdosage (10) ]. |
| Oxycodone | warnings and precautions | Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine/day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer. |
Every other medicine the hydromorphone label names
| Medicine named | Section | What the label says |
|---|---|---|
| Oxymorphone | warnings and precautions | … 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer. |
| Phenelzine | drug interactions | Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (…). If urgent use of an opioid is necessary, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and … patients taking MAOIs or within 14 days of stopping such treatment. Examples: Phenelzine, tranylcypromine, and linezolid. |
| Pregabalin | drug interactions | Benzodiazepines and other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. … relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), other opioids, alcohol. |
| Tramadol | drug interactions | Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. … affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat … |
| Tranylcypromine | drug interactions | Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (…). If urgent use of an opioid is necessary, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and … MAOIs or within 14 days of stopping such treatment. Examples: Phenelzine, tranylcypromine, and linezolid. |
| Trazodone | drug interactions | Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. … drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat … |
Other labels that name hydromorphone
Source: FDA drug label (Hydromorphone Hydrochloride), Rhodes Pharmaceuticals LLC, effective May 14, 2026 (SPL set 37565441-0d95-4743-a695-d7b3326f58a1), via openFDA; the full label on DailyMed
What do FAERS reports show for hydromorphone?
The FDA Adverse Event Reporting System holds 91,453 reports that list hydromorphone among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 28,105 are coded as a death and 17,051 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2018 (23,056, against a median of 2,735 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as hydromorphone?
36 other medicines are given the same way (oral) and in the same FDA class as hydromorphone or labeled mainly for the same use (pain), the same class first. Pain lists all 80 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Acetaminophen and hydrocodone | Pain | 38 labelers | $0.152 per tablet 10-325 mg tablet | No current entry |
| Oxycodone | Pain | 34 labelers | $0.0884 per tablet 5 mg tablet | No current entry |
| Acetaminophen and oxycodone | Pain | 30 labelers | $0.183 per tablet 7.5-325 mg tablet | A presentation being discontinued |
| Tramadol | Pain | 40 labelers | $0.0248 per tablet 50 mg tablet | No current entry |
| Morphine | Pain | 17 labelers | $0.226 per tablet 15 mg tablet | In shortage |
| Acetaminophen and codeine | Pain | 25 labelers | $0.256 per tablet 3 tablet | No current entry |
| Methadone | Pain | 17 labelers | $0.177 per tablet 10 mg tablet | No current entry |
| Oxymorphone | Pain | 9 labelers | n/a | No current entry |
Every medicine labeled for the same conditions as hydromorphone
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does hydromorphone compare with medicines for the same use?
10 side-by-side pages set hydromorphone beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to hydromorphone
- 36 medicines for the same use
- Other opioids
- the pharmacologic class, with prices and generics
- Hydromorphone side effects
- the label's list beside FAERS reports
- Hydromorphone shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other